期刊文献+

青少年晚期肺腺癌克唑替尼替代治疗一例及其护理 被引量:1

原文传递
导出
摘要 肺癌是最常见恶性肿瘤之一,其为全球癌症死亡的首位。肺腺癌(lung adenocarcinoma)是肺部腺上皮细胞恶性肿瘤,属于非小细胞癌。不同于鳞状细胞肺癌,肺腺癌起源于支气管黏膜上皮,少数起源于大支气管的黏液腺。发病率比鳞癌和未分化癌低,发病年龄较小,常见于不抽烟者和女性。多数腺癌起源于较小的支气管,为周围型肺癌。早期一般没有明显的临床症状,往往在胸部X线检查时被发现。
出处 《中华肺部疾病杂志(电子版)》 CAS 2017年第1期115-117,共3页 Chinese Journal of Lung Diseases(Electronic Edition)
  • 相关文献

参考文献4

二级参考文献86

  • 1Frank Bergmann,Irene Esposito,Peter Schirmacher.Pancreatic cancer–Pathology[J].The Chinese-German Journal of Clinical Oncology,2007,6(2):95-101. 被引量:2
  • 2Sasaki T, Rodig SJ, Chirieac LR, et al. The biology and treatment of EMIA-ALK non-small cell lung cancer[ J]. Eur J Cancer, 2010, 46(10) : 1773-1780.
  • 3Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from'never smokers'and are associated with sensitivity of tumors to gefitinib and erlotinib [ J ]. Proc Natl Acad Sci USA, 2004, 101: 13306-13311.
  • 4Gaughan EM, Costa DB. Genotype-driven therapies for non-small-cell-lung cancer: focus on EGFR, KR AS and ALK gene abnormalities[ J]. Ther Adv Med Oncol, 2011, 3(3): 113-125.
  • 5Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer[J]. Clin Cancer Res, 2011, 17(8) : 2081-2086.
  • 6Weickhardt A J, Camidge DR. The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence[J]. Clin Invest, 2011, 1(8): 1119-1126.
  • 7Camidge DR, Bang Y, Kwak EL, et al. Progression-free survival (PFS) from a phase I study of crizotinib ( PF-02341066) in patients with ALK- positive non-small cell lung cancer ( NSCLC ) [J]. J Clin Oncol, 2011 : 29(Suppl. 1 ) : S2501.
  • 8Bang Y, Kwak EL, Shaw AT, et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) [J]. J Clin Oncol, 2010, 28 (Suppl. 1): S3.
  • 9Kwak EL, Camidge DR, Clark J, et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibi-tor, PF-02341066[J]. J Clin Oncol, 2009, 27 (Suppl. 1 ) : S3509.
  • 10Li C, Alvey C, Bello A, et al. Pharmaeokinetics (PK) of erizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors [ J ]. J Clin Oneol, 2011, 29(15) : e13065.

共引文献64

同被引文献10

引证文献1

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部